Anthrax News and Research RSS Feed - Anthrax News and Research

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
OMRF receives $14.5 million grant from NIH to continue research on anthrax

OMRF receives $14.5 million grant from NIH to continue research on anthrax

The National Institutes of Health has awarded the Oklahoma Medical Research Foundation a five-year, $14.5 million grant to continue its research on anthrax and the bacteria's effects on humans. [More]
CDC report blames researcher's haste for bird flu virus mishandling

CDC report blames researcher's haste for bird flu virus mishandling

An investigation into the mistaken shipment of deadly bird flu virus from a government laboratory earlier this year found that a scientist took shortcuts to speed up the work and accidentally contaminated the samples, the Centers for Disease Control and Prevention reported Friday. [More]
Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™. [More]
Viewpoints: Medicare's future finances; 'promising deal' on VA; Texas 'war on abortion'

Viewpoints: Medicare's future finances; 'promising deal' on VA; Texas 'war on abortion'

Medicare got some good news Monday, when the trustees who oversee its finances announced that the fund that pays for hospital care will remain solvent until 2030, four years longer than its forecast from last year. [More]

Senate could vote on VA nominee's confirmation before the August break

Meanwhile, Health and Human Services Secretary Sylvia Burwell named Leslie Dach, a former Wal-Mart vice president, to be a senior adviser as part of Burwell's effort to head off difficulties in the upcoming health law enrollment period. [More]
WIRB-Copernicus Group acquires Alliance Biosciences

WIRB-Copernicus Group acquires Alliance Biosciences

WIRB-Copernicus Group, the world's largest provider of regulatory and ethical review services for clinical research, announced today that it has acquired Alliance Biosciences. Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States. [More]
First Edition: July 24, 2014

First Edition: July 24, 2014

Today's headlines include more analysis of this week's conflicting appeals courts' decisions regarding a key part of the health law. [More]
Viewpoints: 'Entitlement meltdown;' improving Medicare Advantage; 'sloppy work habits' at CDC

Viewpoints: 'Entitlement meltdown;' improving Medicare Advantage; 'sloppy work habits' at CDC

Each day, 10,000 baby boomers retire and begin receiving Medicare and Social Security benefits. And while five workers supported the benefits of each retiree in 1960, there will be only two workers funding each retiree by 2030. Those who dismiss long-term budget projections should re-read the last paragraph. The retirement of 77 million baby boomers into Social Security and Medicare is not a theoretical projection. Demography is destiny (Sen. Rob Portman, R-Ohio, 7/21). [More]
Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®). [More]
First Edition: July, 21, 2014

First Edition: July, 21, 2014

Today's headlines include a story about an effort by regulators to widen insurer networks, as well as a range of other health policy developments. [More]
First Edition: July 18, 2014

First Edition: July 18, 2014

Today's headlines include reports from the marketplace, including UnitedHealthcare's move toward the health law's insurance marketplaces and the latest on the Securities and Exchange Commission investigation into insider trading related to a health policy change. [More]
Research shows promise to speed up drug discovery for deadly diseases

Research shows promise to speed up drug discovery for deadly diseases

Antibiotic resistance is depleting our arsenal against deadly diseases and infections, such as tuberculosis and Staph infections, but recent research shows promise to speed up the drug discovery process. [More]
First Edition: July 15, 2014

First Edition: July 15, 2014

Today's headlines include news about how some states are planning to address their backlogs of new Medicaid enrollees. [More]
CDC closes labs after anthrax, flu accidents

CDC closes labs after anthrax, flu accidents

Federal government labs in Atlanta were temporarily shut after it was discovered they had improperly sent potentially deadly pathogens, including anthrax, botulism and virulent bird flue virus, to other labs. [More]
First Edition: July 14, 2014

First Edition: July 14, 2014

Today's headlines include coverage of Medicare, the health law and veterans' care policy issues as well as reports from the campaign trail. [More]
Viewpoints: Nothing in health care is free; Obamacare opponents lack facts; 'Nurse Jackie' and the ER

Viewpoints: Nothing in health care is free; Obamacare opponents lack facts; 'Nurse Jackie' and the ER

The Department of Health and Human Services released a report Friday declaring that 76 million Americans with private insurance became eligible for more preventive services with no out-of-pocket fees as a result of the 2010 healthcare law, the Patient Protection and Affordable Care Act (a.k.a. Obamacare). Because Democrats are counting on female voters to help them at the polls in November, the report highlighted how women had been helped by that aspect of Obamacare. [More]
Viewpoints: Abortion rights buffer; coming 'freakout' on health law; repercussions of malaria prevention

Viewpoints: Abortion rights buffer; coming 'freakout' on health law; repercussions of malaria prevention

A Unanimous Supreme Court: Abortion Rights Lose A Buffer
Yet on Thursday the Supreme Court, in McCullen v. Coakley, struck down that law for violating the First Amendment. [More]
Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE). [More]
First Edition: June 20, 2014

First Edition: June 20, 2014

Today's early morning highlights from the major news organizations, including reports about a new poll of showing a majority of those signing up for marketplace plans had been uninsured before and the Obama administration's decision to extend marriage benefits, including family leave, to same-sex couples. [More]
PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. [More]